The mucopolysaccharidoses, The Metabolic and Molecular Bases of Inherited Disease, pp.3421-52, 2001. ,
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy, European Journal of Pediatrics, vol.7, issue.3 ,
DOI : 10.1007/s00431-007-0635-4
A clinical and genetic study of Hunter's syndrome. 2 Differences between the mild and severe forms, Journal of Medical Genetics, vol.19, issue.6, pp.408-419, 1982. ,
DOI : 10.1136/jmg.19.6.408
The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life, Orphanet Journal of Rare Diseases, vol.8, issue.1, p.101, 2013. ,
DOI : 10.1186/1750-1172-6-72
A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome), Genetics in Medicine, vol.25, issue.8, pp.465-73, 2006. ,
DOI : 10.1097/01.gim.0000232477.37660.fb
The role of enzyme replacement therapy in severe Hunter syndrome???an expert panel consensus, European Journal of Pediatrics, vol.19, issue.1, pp.181-189, 2012. ,
DOI : 10.1007/s00431-011-1606-3
A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4???7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy, Genetics in Medicine, vol.38, issue.6, pp.435-476, 2014. ,
DOI : 10.1007/BF00973157
Idursulfase treatment of Hunter syndrome in children younger than 6 years: Results from the Hunter Outcome Survey, Genetics in Medicine, vol.51, issue.2, pp.102-111, 2011. ,
DOI : 10.1097/GIM.0b013e318206786f
First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: Case observations from the Hunter Outcome Survey (HOS), European Journal of Medical Genetics, vol.53, issue.6, pp.371-378, 2010. ,
DOI : 10.1016/j.ejmg.2010.07.013
Enzyme replacement therapy for mucopolysaccharidosis II from 3???months of age: a 3-year follow-up, Acta Paediatrica, vol.77, issue.1, pp.42-49, 2012. ,
DOI : 10.1111/j.1651-2227.2011.02385.x
Guideline for diagnosis, follow-up and treatment of mucopolysaccharidoses type II or Hunter disease, Arch Argent Pediatr, vol.109, pp.175-81, 2011. ,
Multidisciplinary Management of Hunter Syndrome, PEDIATRICS, vol.124, issue.6, pp.1228-1267, 2009. ,
DOI : 10.1542/peds.2008-0999
Quality of life questionnaires for children and adolescents, 2006. ,
The KIDSCREEN-27 quality of life measure for children and adolescents: psychometric results from a cross-cultural survey in 13 European countries, Quality of Life Research, vol.50, issue.8, pp.1347-56, 2007. ,
DOI : 10.1007/s11136-007-9240-2
KIDSCREEN-52 quality-of-life measure for children and adolescents, Expert Review of Pharmacoeconomics & Outcomes Research, vol.5, issue.3, pp.353-64, 2005. ,
DOI : 10.1586/14737167.5.3.353
Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome), PEDIATRICS, vol.121, issue.2, pp.377-86, 2008. ,
DOI : 10.1542/peds.2007-1350
Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease, Orphanet Journal of Rare Diseases, vol.6, issue.1, p.72, 2011. ,
DOI : 10.1136/hrt.2005.063818
Hearing loss in patients with mucopolysaccharidosis II: Data from HOS ??? the Hunter Outcome Survey, Journal of Inherited Metabolic Disease, vol.25, issue.2, pp.343-53, 2012. ,
DOI : 10.1007/s10545-011-9378-5
Hearing Loss in Hunter??s Syndrome-Mucopolysaccnaridosis II, Ear and Hearing, vol.5, issue.4, pp.243-249, 1984. ,
DOI : 10.1097/00003446-198407000-00009